Our Science
Building a global leading
synthetic lethality product pipeline
Our Science
Approach

Approach

The latest data show that cancer has become the second leading cause of death in the world causing 10 million people’s death each year globally. There are huge unmet medical needs for cancer treatment. Since foundation in 2009, IMPACT Therapeutics has been dedicated to the discovery and development of novel anti-cancer therapeutics with global rights, building a global leading synthetic lethality product pipeline to address unmet medical needs and make an impact on cancer treatment.

Synthetic Lethality

Genomic instability is one of the hallmarks of cancer cells, and the resultant mutations render cancer cells more dependent on alternative pathways for survival and proliferation, so these cancer cells are more vulnerable to targeted perturbations on those alternative pathways – a phenomenon known as synthetic lethality.

 

Synthetic lethality is an especially attractive and effective approach to targeting some common oncogenes that have been traditionally considered as undruggable. Synthetic lethality also has the potential to overcome the therapeutic resistance caused by new mutations that often occur with the treatment of conventional targeted therapies. Furthermore, therapies addressing synthetic lethality targets can have anti-tumor effects that are complementary to or synergistic with therapeutics employing other mechanisms. Synthetic lethality can be exploited as a drug development approach to selectively target cancer cells with certain mutations, for example, deficiencies in DNA damage response (DDR), and we see this approach usher in a new paradigm for targeted anti-cancer therapy.

Pipeline

Product

Target

Pre-clinical

IND

Ph I

Ph II

Ph III

Marketed

Rights

Collaborations

IMP4297
Senaparib
PARP1/2
Ovarian Cancer (FLAMES Study, 1L maintenance)
Ovarian Cancer (SABRINA Study, 3L+,BRCAm)*Pivotal study
Cell Lung Cancer (combo with Temozolomide)*ODD
China Commercial
Partnership with
Huadong Medicine
IMP4297
Senaparib
Click Hide

Senaparib, discovered and developed by IMPACT, is a potent and novel PARP1/2 inhibitor. Its distinctive molecular structure ensures exceptional target selectivity and wide therapeutic window.

The Phase III registrational study (FLAMES) evaluating Senaparib as a first-line maintenance therapy in advanced ovarian cancer patients (all-comers) has met its primary endpoint, and the the results have been published in the internationally renowned medical journal Nature Medicine.

Senaparib Capsules (派舒宁® )has received marketing authorization in China from National Medical Products Administration (NMPA) as monotherapy for the maintenance treatment of adult patients with advanced epithelial (FIGO Stages III and IV) high-grade ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy



IMP7068
WEE1
 
IMP7068
Click Hide
IMPACT Therapeutics has identified a novel, potent, and selective WEE1 inhibitor IMP7068. IMP7068 completed phase I clinical study
IMP9064
ATR
 
IMP9064
Click Hide
IMP9064, developed by IMPACT, is a potent and highly selective ATR inhibitor. Studies demonstrated that IMP9064 has good oral absorption, and anti-tumor activities in vitro against a broad range of solid tumor cell lines and in vivo against tumor xenograft models. IMP9064 is currently in phase 2 study
IMP1734
PARP1-selective
 
Global Partnership with
Eikon Therapeutics
IMP1734
IMP1707
PARP1-selective
 
IMP1707
IMP13
USP1
 
IMP13
IMP08
ATM
 
IMP08
IMP10
CHK1/2
 
IMP10
IMP5471
Hedgehog
 
IMP5471
中国临床试验
全球临床试验
Partnership
Mutual achievement with professional attitude

In June 2023, IMPACT entered into a global license and collaboration agreement with Eikon Therapeutics for PARP1 selective inhibitors including IMP1734. Eikon received an exclusive license from IMPACT to co-develop, register, manufacture, and commercialize IMP1734 and other PARP1 selective inhibitors globally, excluding Greater China.

 

In December 2023, IMPACT entered into commercial partnership with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd, a subsidiary of Huadong Medicine Co., Ltd (SZ.000963) for promoting Senaparib. Huadong Medicine received exclusive promotion rights of Senaparib in mainland China.

 

We intend to continue exploring partnerships through strategic collaborations including licensing arrangements, co-development and co-commercialization arrangements to maximize the clinical and commercial value of our drug candidates.

Our products
Lead the new life

Senaparib, discovered and developed by IMPACT, is a potent and novel PARP1/2 inhibitor. Its distinctive molecular structure ensures exceptional target selectivity and wide therapeutic window.
The Phase III registrational study (FLAMES) evaluating Senaparib as a first-line maintenance therapy in advanced ovarian cancer patients (all-comers) has met its primary endpoint, and the the results have been published in the internationally renowned medical journal Nature Medicine.
Senaparib Capsules (派舒宁® )has received marketing authorization in China from National Medical Products Administration (NMPA) as monotherapy for the maintenance treatment of adult patients with advanced epithelial (FIGO Stages III and IV) high-grade ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy.

Download the label for the product